||This is your first and only opportunity to listen to the most advanced clinical case studies from Nektar Therapeutics and Amgen which explore the use of IL-2 to enhance the expansion and activation of the Treg cells. Delve deeper with expert insights from Roche and ILTOO Pharma to understand how IL-2 at low doses could selectively stimulate Treg cells.
Identify yourself as a leader in this community and join the discussion exploring the challenges in translating a proof of concept in autoimmune therapies from animal models to clinic. This meeting will provide the platform for conversations to be had to accelerate the clinical translation of Treg directed therapies.
Conference Only (Earlybird ends Feb 23): USD 1999
Conference Only (Earlybird ends Mar 23): USD 2199
Conference Only (Earlybird ends Apr 20): USD 2399
Conference Only: USD 2799
Conference Academic Only (Earlybird ends Feb 23): USD 1399
Conference Academic Only (Earlybird ends Mar 23): USD 1599
Conference Academic Only (Earlybird ends Apr 20): USD 1799
Conference Academic Only: USD 1999
Workshop Only: USD 499
Speakers: Chris Haqq, Kevin Gorski, Nadia Tchao, David Wraith, Andrew Scharenberg, Simrit Parmar, Robert Plenge, Stephen Miller, Todd Brusko, Jérémie Mariau, Laurence Turka, Jason Fontenot, Leonard Dragone, Jonathan Zalevsky, Aaron Winkler, David Klatzmann, Jonathan Esensten, Leslie Kean, Annalisa D’Andrea, Rosa Bacchetta, Qizhi Tang, Dennis Kasper, Stephane Boissel, Pierre Heimendinger, Rose Szabady, David Hafler
Westin Boston Waterfront
425 Summer Street, Boston, MA 02210, United States
Tuesday May 22, 2018 at 8:00 am (ends Thursday May 24, 2018 at 4:00 pm)